Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 33Breast 8Gynecologic 7Gastrointestinal 7Lymphoid 2Classical hematology 2Thoracic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Lymphoma, Non-Hodgkin 5Multiple Myeloma 3Wilms Tumor 2Sarcoma 2Rhabdomyosarcoma 2Rhabdoid Tumor 2Prostatic Neoplasms 2Pancreatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Medulloblastoma 2Lymphoma 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Glioma 2Ependymoma 2Central Nervous System Neoplasms 2Breast Neoplasms 2Xanthogranuloma, Juvenile 1Triple Negative Breast Neoplasms 1Thrombocytosis 1Sarcoma, Ewing 1Primary Myelofibrosis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1

Interventions

Vorinostat 3Azacitidine 3venetoclax 2trametinib 2ruxolitinib 2pertuzumab 2palbociclib 2olaparib 2durvalumab 2dabrafenib 2copanlisib 2aflibercept 2abiraterone 2Sunitinib 2Specimen Handling 2Sirolimus 2Nivolumab 2Immunoglobulin G 2HhAntag691 2Doxorubicin 2Disulfides 2Dasatinib 2Cyclophosphamide 2Biopsy 2Afatinib 2Ado-Trastuzumab Emtansine 22C4 antibody 2ulixertinib 1tremelimumab 1trastuzumab biosimilar HLX02 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Prostatic Neoplasms × olaparib × Lymphoid × Clear all
NCT03878524 2024-03-04

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

OHSU Knight Cancer Institute

Phase 1 Terminated
2 enrolled
BreastClassical hematologyGastrointestinalGenitourinaryLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Blast Crisis, Breast Neoplasms, Hodgkin Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Myeloproliferative Disorders, Neoplasm Metastasis, Pancreatic Neoplasms, Prostatic Neoplasms, Thrombocytosis, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative, Primary Myelofibrosis

NCT03205176 2021-05-06

AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas

AstraZeneca

Phase 1 Completed
49 enrolled
BreastGastrointestinalGenitourinaryGynecologicLymphoid

Breast Neoplasms, Lymphoma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡